Accelerating the Future of RNAi Drug Discovery with AI
Accelerating the Future of RNAi Drug Discovery with AI Anonymous (not verified) Wed, 2 Sep 2026 - 14:44
Company profile
Alnylam Pharmaceuticals, Inc.
Pipeline24 assets
- NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3
- ZilebesiranRNAi therapeutic / CardiovascularHypertensionPhase 3REVERSIR HypertensionPhase 1
- RapirosiranALN-HSD / HSD / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2
- ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / MetabolicDiabetic Kidney DiseasePhase 2
- ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / MetabolicType 2 Diabetes MellitusPhase 1
- ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / MetabolicObesity & Weight ManagementPhase 1
- ALN-PNPALN-PNP / PNP / RNAi therapeutic / MetabolicNon-Alcoholic Fatty Liver Disease (NAFLD)Phase 1
- ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / MetabolicDyslipidemiaPhase 1
- ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1
- Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/OtherMyasthenia GravisPhase 3Geographic AtrophyPhase 3
- MivelsiranALN-APP / APP / RNAi therapeutic / NeuroscienceCerebral Amyloid Angiopathy (CAA)Phase 2Alzheimer’s DiseasePhase 1
- ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / NeuroscienceHuntington’s DiseasePhase 1
- ALN-5288ALN-5288 / MAPT / RNAi therapeutic / NeuroscienceAlzheimer’s DiseasePhase 1
- ALN-SODALN-SOD / SOD1 / RNAi therapeutic / NeuroscienceSOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1
- ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / NeuroscienceParkinson’s DiseasePhase 1
- Cemdisiran (+Pozelimab)RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 3
- ALN-6400ALN-6400 / PLG / RNAi therapeutic / HematologyBleeding DisordersPhase 2
- AG-236ALN-TMP / TMP / RNAi therapeutic / HematologyPolycythemia VeraPhase 1
- ALN-CFBALN-CFB / CFB / RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 1
- Elebsiran (+Tobevibart)RNAi therapeutic / OtherHepatitis D Virus InfectionPhase 2
- ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / OtherHepatocellular CarcinomaPhase 1
- ALN-4285ALN-4285 / RNAi therapeutic / OtherHealthy VolunteersPhase 1
- ALN-4915ALN-4915 / RNAi therapeutic / OtherHealthy VolunteersPhase 1
- ALN-F1202ALN-F1202 / RNAi therapeutic / OtherHealthy VolunteersPhase 1
Latest news4 items
All newsAdvancing Earlier Diagnosis and Coordinated Care in ATTR-CM
Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM Anonymous (not verified) Wed, 26 Aug 2026 - 17:27
Scaling with Purpose: Alnylam Publishes 2025 Corporate Responsibility Report
Scaling with Purpose: Alnylam Publishes 2025 Corporate Responsibility Report Anonymous (not verified) Tue, 19 May 2026 - 17:07
2025 Corporate Responsibility Report
2025 Corporate Responsibility Report ozaki Mon, 18 May 2026 - 18:42 LEARN MORE › 2025 Corporate Responsibility Report Alnylam's 2025 report details our progress against our corporate responsibility goals Our News 11 news-letter alnylam-2030 top-alinged cr-slide